February 22, 2016
Corium Announces Positive Topline Results From Phase 1 Clinical Study of Transdermal CorplexTM Memantine as a Potential Treatment of Alzheimer’s Disease
Demonstrates Pharmacokinetic Profile Supporting the Feasibility of Sustained Transdermal Delivery Webcast and Conference Call Today at 5:00 p.m. ET ( 2:00 p.m. PT ) MENLO PARK, Calif. , Feb. 22, 2016 (GLOBE NEWSWIRE) — Corium International, Inc. (Nasdaq:CORI), a commercial-stage…